| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9415 | 2011 |
| Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes J Li, M Zhao, P He, M Hidalgo, SD Baker Clinical Cancer Research 13 (12), 3731-3737, 2007 | 353 | 2007 |
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib G Cusatis, V Gregorc, J Li, A Spreafico, RG Ingersoll, J Verweij, ... Journal of the National Cancer Institute 98 (23), 1739-1742, 2006 | 288 | 2006 |
| Oncometabolites suppress DNA repair by disrupting local chromatin signalling PL Sulkowski, S Oeck, J Dow, NG Economos, L Mirfakhraie, Y Liu, ... Nature 582 (7813), 586-591, 2020 | 274 | 2020 |
| Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair PL Sulkowski, RK Sundaram, S Oeck, CD Corso, Y Liu, S Noorbakhsh, ... Nature genetics 50 (8), 1086-1092, 2018 | 218 | 2018 |
| Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients J Li, G Cusatis, J Brahmer, A Sparreboom, RW Robey, SE Bates, ... Cancer biology & therapy 6 (3), 432-438, 2007 | 211 | 2007 |
| BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. A Ribas, KB Kim, LM Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... Journal of Clinical Oncology 29 (15_suppl), 8509-8509, 2011 | 193 | 2011 |
| Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice S Padhye, S Banerjee, D Chavan, S Pandye, KV Swamy, S Ali, J Li, ... Pharmaceutical research 26, 2438-2445, 2009 | 173 | 2009 |
| Phase I study of ON 01910. Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors A Jimeno, J Li, WA Messersmith, D Laheru, MA Rudek, M Maniar, ... Journal of Clinical Oncology 26 (34), 5504-5510, 2008 | 137 | 2008 |
| Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib NP Van Erp, H Gelderblom, MO Karlsson, J Li, M Zhao, J Ouwerkerk, ... Clinical cancer research 13 (24), 7394-7400, 2007 | 132 | 2007 |
| CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors J Li, MO Karlsson, J Brahmer, A Spitz, M Zhao, M Hidalgo, SD Baker Journal of the National Cancer Institute 98 (23), 1714-1723, 2006 | 129 | 2006 |
| Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors PM LoRusso, MJ Edelman, SL Bever, KM Forman, MJ Pilat, MF Quinn, ... Journal of clinical oncology 30 (32), 4011-4016, 2012 | 125 | 2012 |
| A phase I dose-escalation study of oral BR-DIM (BioResponse 3, 3′-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer EI Heath, LK Heilbrun, J Li, U Vaishampayan, F Harper, P Pemberton, ... American journal of translational research 2 (4), 402, 2010 | 114 | 2010 |
| Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients … PM LoRusso, J Li, A Burger, LK Heilbrun, EA Sausville, SA Boerner, ... Clinical Cancer Research 22 (13), 3227-3237, 2016 | 108 | 2016 |
| Relationship of systemic exposure to unbound docetaxel and neutropenia SD Baker, J Li, AJ Ten Tije, WD Figg, W Graveland, J Verweij, ... Clinical pharmacology & therapeutics 77 (1), 43-53, 2005 | 108 | 2005 |
| Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients J Li, J Brahmer, W Messersmith, M Hidalgo, SD Baker Investigational new drugs 24, 291-297, 2006 | 100 | 2006 |
| Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy J Li, MH Bluth Pharmacogenomics and personalized medicine, 11-33, 2011 | 92 | 2011 |
| Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients N Sanai, J Li, J Boerner, K Stark, J Wu, S Kim, A Derogatis, S Mehta, ... Clinical Cancer Research 24 (16), 3820-3828, 2018 | 87 | 2018 |
| Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry M Zhao, C Hartke, A Jimeno, J Li, P He, Y Zabelina, M Hidalgo, SD Baker Journal of chromatography B 819 (1), 73-80, 2005 | 84 | 2005 |
| Clinical Pharmacokinetics and Exposure‐Toxicity Relationship of a Folate‐Vinca Alkaloid Conjugate EC145 in Cancer Patients J Li, EA Sausville, PJ Klein, D Morgenstern, CP Leamon, RA Messmann, ... The Journal of Clinical Pharmacology 49 (12), 1467-1476, 2009 | 81 | 2009 |
Nader Sanai, MDDirector of Neurosurgical Oncology, Barrow Neurological Institutebnaneuro.net üzerinde doğrulanmış e-posta adresine sahip